Thiethylperazine

WARNING: This product is for research use only, not for human or veterinary use.

MedKoo CAT#: 318860

CAS#: 1420-55-9

Description: Thiethylperazine is an antiemetic of the phenothiazine class. Though it was never licensed or used as an antipsychotic, it may have such effects. Thiethylperazine activates the transport protein ABCC1 that clears beta-amyloid from brains of mice.

Chemical Structure

Thiethylperazine

CAS# 1420-55-9

Instruction

Theoretical Analysis

MedKoo Cat#: 318860
Name: Thiethylperazine
CAS#: 1420-55-9
Chemical Formula: C22H29N3S2
Exact Mass: 399.18
Molecular Weight: 399.615
Elemental Analysis: C, 66.12; H, 7.32; N, 10.52; S, 16.05

Price and Availability

Size	Price	Availability	Quantity
1g	USD -1
2g	USD -1
5g	USD -1
Bulk inquiry Welcome, Customer: Please do not inquire quote if your intended use is for a patient since our products are for research use and for chemical synthesis use, not for human use . For in-stock products, we listed price in the web page. You may inquire prices for which sizes were not listed. If no price is listed, this means the product is not in stock at the moment, which may be available via custom synthesis. For cost-effective reason, minimum order of 1g is requested (typically very expensive). The lead time is usually 2-4 months. Quote of less than 1g will not be provided. MedKoo may not offer quote for below reasons: (1) current available synthetic method appears to be extremely expensive which is obviously not affordable to most customers; (2) Key raw material to make the product is temporally not available; (3) DEA controlled substances; (4) the product is under patent protection in customer’s country.

Synonym: Thiethylperazine; Torecan; Norzine.

IUPAC/Chemical Name: 2-(ethylthio)-10-[3-(4-methylpiperazin-1-yl)propyl]-10H-phenothiazine

InChi Key: XCTYLCDETUVOIP-UHFFFAOYSA-N

InChi Code: InChI=1S/C22H29N3S2/c1-3-26-18-9-10-22-20(17-18)25(19-7-4-5-8-21(19)27-22)12-6-11-24-15-13-23(2)14-16-24/h4-5,7-10,17H,3,6,11-16H2,1-2H3

SMILES Code: CN1CCN(CCCN2C3=C(C=CC=C3)SC4=CC=C(SCC)C=C24)CC1

Appearance: Solid powder

Purity: >98% (or refer to the Certificate of Analysis)

Shipping Condition: Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition: Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility: Soluble in DMSO, not in water

Shelf Life: >2 years if stored properly

Drug Formulation: This drug may be formulated in DMSO

Stock Solution Storage: 0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code: 2934.99.9001

More Info:

Instruction:

View handling instruction

Biological target:
In vitro activity:
In vivo activity:

Preparing Stock Solutions

The following data is based on the product molecular weight 399.62 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Concentration / Solvent Volume / Mass	1 mg	5 mg	10 mg
1 mM	1.15 mL	5.76 mL	11.51 mL
5 mM	0.23 mL	1.15 mL	2.3 mL
10 mM	0.12 mL	0.58 mL	1.15 mL
50 mM	0.02 mL	0.12 mL	0.23 mL

Formulation protocol:
In vitro protocol:
In vivo protocol:

Molarity Calculator

Calculate the mass, volume, or concentration required for a solution.

Mass

Concentration

Volume

M. Wt* g/mol

*When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and SDS / CoA (available online).

Reconstitution Calculator

The reconstitution calculator allows you to quickly calculate the volume of a reagent to reconstitute your vial. Simply enter the mass of reagent and the target concentration and the calculator will determine the rest.

Volume (to add to vial)

Mass (in vial)

Desired Reconstitution Concentration

Dilution Calculator

Calculate the dilution required to prepare a stock solution.

Concentration 1

Volume 1

Concentration 2

Volume 2

1: Majewska M, Kołodziej M, Szponar J, Drelich G, Danielewicz P, Kostek H. [Noncardiogenic pulmonary edema in the course of poisoning with clozapine, ketoprofen and thiethylperazine]. Przegl Lek. 2012;69(8):618-20. Polish. PubMed PMID: 23243946.

2: Rossetti G, Livio F, Roulet E, Hofer MF. Anaphylactic reaction and unrelated, subsequent, known side effects during therapy with thiethylperazine. Pediatr Allergy Immunol. 2005 Aug;16(5):453-5. PubMed PMID: 16101941.

3: Briani C, Cagnin A, Chierichetti F, Tiberio M, Battistin L, Pizzolato G. Thiethylperazine-induced parkinsonism: in vivo demonstration of dopamine D2 receptors blockade. Eur J Neurol. 2004 Oct;11(10):709-10. PubMed PMID: 15469457.

4: Czeizel AE, Vargha P. Case-control study of teratogenic potential of thiethylperazine, an anti-emetic drug. BJOG. 2003 May;110(5):497-9. PubMed PMID: 12742335.

5: Toll A, Campo-Pisa P, González-Castro J, Campo-Voegeli A, Azón A, Iranzo P, Lecha M, Herrero C. Subacute cutaneous lupus erythematosus associated with cinnarizine and thiethylperazine therapy. Lupus. 1998;7(5):364-6. PubMed PMID: 9696142.

6: Mendenhall A, Hoyt DB. Incompatibility of ketorolac tromethamine with haloperidol lactate and thiethylperazine maleate. Am J Hosp Pharm. 1994 Dec 1;51(23):2964. PubMed PMID: 7879809.

7: Budrewicz S, Ejma M. [Dyskinesis after a single dose of thiethylperazine during the first trimester of pregnancy]. Pol Tyg Lek. 1994 Feb 21-28;49(8-9):205-6. Polish. PubMed PMID: 8084830.

8: Lossos IS, Mevorach D, Oren R. Thiethylperazine treatment of gastroparesis diabeticorum. Ann Pharmacother. 1992 Jul-Aug;26(7-8):1016. PubMed PMID: 1504386.

9: Jiménez-Jiménez FJ, Vazquez A, Garcia-Ruiz P, Garcia-Urra D, De Seijas EV. Chronic hemidystonia following acute dystonic reaction to thiethylperazine. J Neurol Neurosurg Psychiatry. 1991 Jun;54(6):562. PubMed PMID: 1880525; PubMed Central PMCID: PMC488605.

10: Diaz-Rubio E, Martin M, Rosell R, Valerdi JJ, Gonzalez-Larriba JL, Barriga JJ. The antiemetic efficacy of thiethylperazine and methylprednisolone versus thiethylperazine and placebo in breast cancer patients treated with adjuvant chemotherapy (fluorouracil, doxorubicin and cyclophosphamide). A randomized, double-blind, cross-over trial. Acta Oncol. 1991;30(3):339-42. PubMed PMID: 2036244.

11: Brennum J. [Extrapyramidal side effects after long-term treatment with thiethylperazine]. Ugeskr Laeger. 1988 Nov 14;150(46):2827. Danish. PubMed PMID: 3206698.

12: Khanderia U. Recurrent dystonic reactions induced by thiethylperazine. Drug Intell Clin Pharm. 1985 Jul-Aug;19(7-8):550-1. PubMed PMID: 4028959.

13: Sulkava R. Thiethylperazine and tardive dyskinesia. Acta Neurol Scand. 1984 Nov;70(5):369-72. PubMed PMID: 6507047.

14: Corea RT. Dislocation of temporomandibular joints resulting from thiethylperazine maleate therapy. Ceylon Med J. 1984 Jun;29(2):117-8. PubMed PMID: 6529785.

15: Prusiński A, Kozubski W, Szymańska R, Mochecka-Thoelke A. [Neurological side effects after using thiethylperazine]. Pol Tyg Lek. 1983 Sep 26;38(39):1227-8. Polish. PubMed PMID: 6585781.

16: Vlachos P. Dystonic reactions following thiethylperazine in children. Toxicol Lett. 1982 Oct;13(3-4):183-4. PubMed PMID: 7147262.

17: [Tardive dyskinesia - metoclopramide and thiethylperazine]. Lakartidningen. 1981 Aug 5;78(32-33):2751-2. Swedish. PubMed PMID: 7278451.

18: Colls BM, Ferry DG, Gray AJ, Harvey VJ, McQueen EG. The antiemetic activity of tetrahydrocannabinol versus metoclopramide and thiethylperazine in patients undergoing cancer chemotherapy. N Z Med J. 1980 Jun 25;91(662):449-51. PubMed PMID: 6250106.

19: Lacouture PG, Mitchell AA, Lovejoy FH Jr. Thiethylperazine (Torecan)-associated dystonic reactions in children. Pediatrics. 1979 Dec;64(6):954-5. PubMed PMID: 514725.

20: Kief HK. [Dyskinesia tarda caused by long-term administration of thiethylperazine (Torecan) prescribed for "dizziness"]. Ned Tijdschr Geneeskd. 1979 Aug 25;123(34):1460-3. Dutch. PubMed PMID: 481619.

Your view history